Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Provided By GlobeNewswire
Last update: Aug 8, 2024
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate in H2 2024
